Login

Nilüfer Sertdemir

ORCID: 0000-0002-4138-7454
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5007741158
Research Areas
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Genetic factors in colorectal cancer
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • RNA modifications and cancer
  • Molecular Biology Techniques and Applications

Kocaeli Üniversitesi
 2019-2022

 TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing
OPENALEX - Publications 
Hakan Savlı Nilüfer Sertdemir Duygu Aydın Bilge Dursun Ömer Kurtaş and 13 more Seda Reka Deniz Sunnetci‐Akkoyunlu Seda Eren‐Keskin Kazım Uygun Ercan Özden Ulaş Işık Devrim Çabuk Gulhan Demir Eda Guzdolu Merve Gökbayrak Maksut Görkem Aksu Nuh Zafer Cantürk Naci Çine

10.1016/j.jbiotec.2019.05.005 article EN Journal of Biotechnology 2019-05-14
 The diagnostic importance of pathogenic variants and variant coexistence determined by NGS-based liquid biopsy approach in patients with lung adenocarcinoma
OPENALEX - Publications 
Naci Çine Emin Ali Sen Gulhan Demir Merve Gökbayrak Eda Guzdolu and 11 more Nilüfer Sertdemir Duygu Aydın Ömer Kurtaş Seda Reka Deniz Sunnetci‐Akkoyunlu Seda Eren‐Keskin Kazım Uygun Devrim Çabuk Maksut Görkem Aksu Nuh Zafer Cantürk Hakan Savlı

10.1016/j.mcp.2022.101819 article EN Molecular and Cellular Probes 2022-04-29
 The Mutation Profiles of K-RAS/N-RAS Genes in Metastatic Colorectal Cancer Patients
OPENALEX - Publications 
Seda EREN KESKİN Eda Guzdolu Nilüfer Sertdemir Gulhan Demir Deniz Sünnetçi Akkoyunlu and 3 more Devrim Çabuk Naci Çine Hakan Savlı

Objective: RAS genes are members of the RAS/Mitogen activated protein kinase pathway which is induced by Epidermal Growth Factor Receptor (EGFR). Mutations in this trigger cancer development. In colorectal cancer, mutations cause resistance to EGRF- targeted therapy. treatment metastatic EGFR’s monoclonal antibodies widely used as chemotherapeutic agents. Kirsten-RAS found 30-50% and N-RAS 2-3% cancer. study, we aimed analyze /N-RAS patients with Methods: One hundred resistant EGFR- therapy...

10.30934/kusbed.1052876 article EN Kocaeli Üniversitesi Sağlık Bilimleri Dergisi 2022-09-30
Coming Soon ...